Timber Pharmaceuticals’ TMB-001 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Congenital Ichthyosis
Shots:
- The US FDA has granted BTD to TMB-001 for the treatment of CI. The preliminary study showed a substantial improvement over available therapy on a clinically significant EPs
- The results from the P-IIb (CONTROL) study of TMB-001 showed a clinical reduction in targeted & overall severity of CI along with a favorable safety profile. The P-IIb (CONTROL) study's sub-analysis revealed that patients treated with TMB-001 had treatment success regardless of the type of CI
- The company has initiated the P-III (ASCEND) trial to evaluate the efficacy & safety of TMB-001 for CI at research centers in the US, Canada, Italy, France & Germany with an expected first patient dosing in June 2022
Ref: Timber Pharmaceuticals | Image: Timber Pharmaceuticals
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
